LBDA Research Centers of Excellence Grant
About the Award:
This award will form a collaboration between the Lewy Body Dementia Association (LBDA) and up to 16 academic centers to establish the LBDA Research Centers of Excellence (RCOE) Program.
The over-arching objectives are:
- Increase patient access nationwide to experts in the diagnosis and management of LBD, and
- Create a clinical trials-ready network of nationally-recognized research centers for trials in LBD.
National research priorities for LBD, which includes dementia with Lewy bodies and Parkinson’s disease dementia, were first developed in 2013 at the Alzheimer’s Disease-Related Dementias (ADRD) Summit organized by the National Institutes of Health (NIH). Updated in 2016, the top priority for LBD research remains unchanged: to initiate clinical trials of new and existing therapies to address symptoms that have the greatest impact on patient function and caregiver burden in LBD.
With historic increases in federal funding for dementia research, major new investments are being made to identify LBD biomarkers. In parallel, industry is increasingly investing in the LBD market. As a result, a more robust research infrastructure is needed to facilitate nationwide clinical trials in both biomarkers and new/existing therapies.
Large scale studies require a standardized approach to patients with LBD across multiple centers of expertise and centralized and standardized data collection. LBDA’s RCOE program will establish this essential foundation. The RCOE program also will act as a signpost for LBD families seeking expert clinical care, resulting in a ready set group of LBD patients across the country for rapid recruitment into therapeutic trials.
Deadline for Applications: September 5th, 2017 at 11:59pm EST
View/Download the Request for Applications (RFA)
Download the Letter of Intent (LOI)
Download the Grant Application